Dementia risk advice introduced into NHS Health Check

Dementia risk advice introduced into NHS Health Check

June 19 2018 Health professionals providing the NHS Health Check service will be expected to give...

Wales announces £100m to shake up NHS and social care services

Wales announces £100m to shake up NHS and social care services

June 14 2018 Wales is to undergo a significant overhaul of NHS and social care services, the...

Welsh pharmacies to supply flu vaccine for care home workers

Welsh pharmacies to supply flu vaccine for care home workers

June 11 2018 Care home workers in Wales will be eligible for free flu vaccination in the 2018-19...

Flu vaccination by GPs sees increase for 2017-18 season

Flu vaccination by GPs sees increase for 2017-18 season

May 30 2018 Flu vaccine uptake among people aged 65 years or over increased to 72.6% for the...

5.4 million patients do not have standard out-of-hours access to GP services

5.4 million patients do not have standard out-of-hours access to GP services

May 11 2018 New data indicates 805 general practices across England do not provide any extended...

  • Dementia risk advice introduced into NHS Health Check

    Dementia risk advice introduced into NHS Health Check

    Tuesday, 19 June 2018 10:15
  • Wales announces £100m to shake up NHS and social care services

    Wales announces £100m to shake up NHS and social care services

    Thursday, 14 June 2018 14:24
  • Welsh pharmacies to supply flu vaccine for care home workers

    Welsh pharmacies to supply flu vaccine for care home workers

    Monday, 11 June 2018 14:07
  • Flu vaccination by GPs sees increase for 2017-18 season

    Flu vaccination by GPs sees increase for 2017-18 season

    Wednesday, 30 May 2018 11:07
  • 5.4 million patients do not have standard out-of-hours access to GP services

    5.4 million patients do not have standard out-of-hours access to GP services

    Friday, 11 May 2018 11:41

adhdDecember 2 2015

Researchers have urged doctors to be cautious if considering prescribing methylphenidate for children or adolescents with attention deficit hyperactivity disorder (ADHD).

A Cochrane review has concluded that the drug may improve teacher-reported ADHD symptoms, teacher-reported general behaviour, and parent-reported quality of life among children and adolescents diagnosed with ADHD. “However, the low quality of the underpinning evidence means that we cannot be certain of the magnitude of the effects.”

The researchers assessed 38 parallel-group trials and 147 cross-over trials, representing over 12,200 patients, and found methylphenidate led to “modest” improvements in ADHD symptoms as a primary outcome. They also found there were improvements in general behaviour and quality of life. However, in all outcomes, the quality of the evidence was judged to be “very low”.

Data for serious adverse events was only reported in nine out of the 185 trials, meaning that while methylphenidate does not appear to be associated with an increased risk of serious adverse events, the quality of the evidence was again very low.

“It was apparent from assessing the included trials that it would have been possible for people involved in the trials to have been aware of which treatment the children were taking,” says Cochrane. “In addition, the reporting of results was not complete in many of the trials, and for some analyses there was variation among trial results.

“Based upon this information, the researchers urge clinicians to be cautious in prescribing methylphenidate, and to weigh up the benefits and risks more carefully.”

Professor Ole Jakob Storebø, a clinical psychologist from the Psychiatric Research Unit in Region Zealand, Denmark, led the team of 18 researchers carrying out the meta-analysis. “This review highlights the need for long-term, large, better-quality randomized trials so that we can determine the average effect of this drug more reliably,” he said.

Co-author Camilla Groth MD added: “This review shows very limited quality evidence for the effects of methylphenidate on children and adolescents with ADHD. Some might benefit, but we still don’t know which patients will do so. Clinicians prescribing methylphenidate must take account of the poor quality of the evidence, monitor treatment carefully, and weigh up the benefits and adverse effects.”

Links:

Cochrane announcement

Cochrane review summary

Ole Jakob Storebø et al. ‘Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)’. Cochrane Library. Published online November 25 2015.

Contract News

June 22 2018 A review into the scheduling of cannabis for medicinal purposes will look for “significant medical and therapeutic benefits” before a decision is made.
June 6 2018 The Royal College of General Practitioners has called for visa regulations to be reviewed to allow more doctors to work as GPs in the NHS. Home Secretary Sajit Javid announced on Sunday...